Literature DB >> 34226537

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity.

L Vanderbeke1, P Van Mol2, Y Van Herck3, F De Smet4, S Humblet-Baron5, K Martinod6, A Antoranz4, I Arijs2, B Boeckx2, F M Bosisio7, M Casaer8, D Dauwe8, W De Wever9, C Dooms10, E Dreesen11, A Emmaneel12, J Filtjens13, M Gouwy14, J Gunst8, G Hermans8, S Jansen15, K Lagrou1, A Liston16, N Lorent17, P Meersseman18, T Mercier1, J Neyts15, J Odent19, D Panovska4, P A Penttila20, E Pollet19, P Proost14, J Qian2, K Quintelier12, J Raes21, S Rex22, Y Saeys12, J Sprooten23, S Tejpar24, D Testelmans10, K Thevissen25, T Van Buyten15, J Vandenhaute13, S Van Gassen12, L C Velásquez Pereira6, R Vos10, B Weynand7, A Wilmer18, J Yserbyt10, A D Garg23, P Matthys13, C Wouters5,13, D Lambrechts2, E Wauters26, J Wauters18.   

Abstract

Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct virus-induced cellular damage. To elucidate the immunopathology underlying COVID-19 severity, we perform cytokine and multiplex immune profiling in COVID-19 patients. We show that hypercytokinemia in COVID-19 differs from the interferon-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced in critical versus mild-moderate COVID-19. Systems modelling of cytokine levels paired with deep-immune profiling shows that classical monocytes drive this hyper-inflammatory phenotype and that a reduction in T-lymphocytes correlates with disease severity, with CD8+ cells being disproportionately affected. Antigen presenting machinery expression is also reduced in critical disease. Furthermore, we report that neutrophils contribute to disease severity and local tissue damage by amplification of hypercytokinemia and the formation of neutrophil extracellular traps. Together our findings suggest a myeloid-driven immunopathology, in which hyperactivated neutrophils and an ineffective adaptive immune system act as mediators of COVID-19 disease severity.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34226537     DOI: 10.1038/s41467-021-24360-w

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  30 in total

Review 1.  Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.

Authors:  Ellen Brisse; Carine H Wouters; Patrick Matthys
Journal:  Cytokine Growth Factor Rev       Date:  2014-10-28       Impact factor: 7.638

2.  Endolymphatic-mastoid shunt operation: results of the 24 cases and revision surgery with the silastic sheet.

Authors:  K Gyo; N Yanagihara
Journal:  Auris Nasus Larynx       Date:  1982       Impact factor: 1.863

3.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

4.  Viral and host factors related to the clinical outcome of COVID-19.

Authors:  Xiaonan Zhang; Yun Tan; Yun Ling; Gang Lu; Feng Liu; Zhigang Yi; Xiaofang Jia; Min Wu; Bisheng Shi; Shuibao Xu; Jun Chen; Wei Wang; Bing Chen; Lu Jiang; Shuting Yu; Jing Lu; Jinzeng Wang; Mingzhu Xu; Zhenghong Yuan; Qin Zhang; Xinxin Zhang; Guoping Zhao; Shengyue Wang; Saijuan Chen; Hongzhou Lu
Journal:  Nature       Date:  2020-05-20       Impact factor: 69.504

5.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.

Authors:  Evangelos J Giamarellos-Bourboulis; Mihai G Netea; Nikoletta Rovina; Karolina Akinosoglou; Anastasia Antoniadou; Nikolaos Antonakos; Georgia Damoraki; Theologia Gkavogianni; Maria-Evangelia Adami; Paraskevi Katsaounou; Maria Ntaganou; Magdalini Kyriakopoulou; George Dimopoulos; Ioannis Koutsodimitropoulos; Dimitrios Velissaris; Panagiotis Koufargyris; Athanassios Karageorgos; Konstantina Katrini; Vasileios Lekakis; Mihaela Lupse; Antigone Kotsaki; George Renieris; Danai Theodoulou; Vassiliki Panou; Evangelia Koukaki; Nikolaos Koulouris; Charalambos Gogos; Antonia Koutsoukou
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

6.  Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia.

Authors:  Qin Liu; Huai Chen; Qingsi Zeng
Journal:  J Infect       Date:  2020-07-11       Impact factor: 6.072

7.  Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients.

Authors:  Linnan Zhu; Penghui Yang; Yingze Zhao; Zhenkun Zhuang; Zhifeng Wang; Rui Song; Jie Zhang; Chuanyu Liu; Qianqian Gao; Qumiao Xu; Xiaoyu Wei; Hai-Xi Sun; Beiwei Ye; Yanan Wu; Ning Zhang; Guanglin Lei; Lingxiang Yu; Jin Yan; Guanghao Diao; Fanping Meng; Changqing Bai; Panyong Mao; Yeya Yu; Mingyue Wang; Yue Yuan; Qiuting Deng; Ziyi Li; Yunting Huang; Guohai Hu; Yang Liu; Xiaoqian Wang; Ziqian Xu; Peipei Liu; Yuhai Bi; Yi Shi; Shaogeng Zhang; Zhihai Chen; Jian Wang; Xun Xu; Guizhen Wu; Fu-Sheng Wang; George F Gao; Longqi Liu; William J Liu
Journal:  Immunity       Date:  2020-07-19       Impact factor: 31.745

Review 8.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

9.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Authors:  Daniel Blanco-Melo; Benjamin E Nilsson-Payant; Wen-Chun Liu; Skyler Uhl; Daisy Hoagland; Rasmus Møller; Tristan X Jordan; Kohei Oishi; Maryline Panis; David Sachs; Taia T Wang; Robert E Schwartz; Jean K Lim; Randy A Albrecht; Benjamin R tenOever
Journal:  Cell       Date:  2020-05-15       Impact factor: 41.582

10.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.

Authors:  Hong-Yi Zheng; Mi Zhang; Cui-Xian Yang; Nian Zhang; Xi-Cheng Wang; Xin-Ping Yang; Xing-Qi Dong; Yong-Tang Zheng
Journal:  Cell Mol Immunol       Date:  2020-03-17       Impact factor: 11.530

View more
  52 in total

Review 1.  Human immune diversity: from evolution to modernity.

Authors:  Adrian Liston; Stephanie Humblet-Baron; Darragh Duffy; An Goris
Journal:  Nat Immunol       Date:  2021-11-18       Impact factor: 25.606

Review 2.  Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.

Authors:  Jasmin Hassan; Charlotte Haigh; Tanvir Ahmed; Md Jasim Uddin; Diganta B Das
Journal:  Pharmaceutics       Date:  2022-05-16       Impact factor: 6.525

3.  Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity.

Authors:  Anoop T Ambikan; Hong Yang; Shuba Krishnan; Sara Svensson Akusjärvi; Soham Gupta; Magda Lourda; Maike Sperk; Muhammad Arif; Cheng Zhang; Hampus Nordqvist; Sivasankaran Munusamy Ponnan; Anders Sönnerborg; Carl Johan Treutiger; Liam O'Mahony; Adil Mardinoglu; Rui Benfeitas; Ujjwal Neogi
Journal:  Cell Syst       Date:  2022-07-08       Impact factor: 11.091

4.  Association of interferon gamma inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1 alpha, interleukin-6, and rs12252 single nucleotide polymorphism of interferon-induced transmembrane protein-3 gene with the severity of COVID-19 infection.

Authors:  Shafia Mulla; Md Maruf Ahmed Molla; S M Ali Ahmed; A K M Akhtaruzzaman; Ahmed Abu Saleh; Shaheda Anwar
Journal:  Egypt J Intern Med       Date:  2022-07-08

5.  Mechanisms of Entry Into the Central Nervous System by Neuroinvasive Pathogens.

Authors:  Navid Valizadeh; Emily A Rudmann; Isaac H Solomon; Shibani S Mukerji
Journal:  J Neuroophthalmol       Date:  2022-02-15       Impact factor: 4.415

6.  A composite ranking of risk factors for COVID-19 time-to-event data from a Turkish cohort.

Authors:  Ayse Ulgen; Sirin Cetin; Meryem Cetin; Hakan Sivgin; Wentian Li
Journal:  Comput Biol Chem       Date:  2022-04-09       Impact factor: 3.737

Review 7.  Myeloid-derived suppressor cells in COVID-19: A review.

Authors:  Yuliya V Perfilyeva; Yekaterina O Ostapchuk; Raikhan Tleulieva; Aykin Kali; Nurshat Abdolla; Vladimir K Krasnoshtanov; Anastassiya V Perfilyeva; Nikolai N Belyaev
Journal:  Clin Immunol       Date:  2022-04-27       Impact factor: 10.190

8.  High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients.

Authors:  P A Penttilä; S Van Gassen; D Panovska; J Wauters; F De Smet; L Vanderbeke; Y Van Herck; K Quintelier; A Emmaneel; J Filtjens; B Malengier-Devlies; K Ahmadzadeh; P Van Mol; D M Borràs; A Antoranz; F M Bosisio; E Wauters; K Martinod; P Matthys; Y Saeys; A D Garg
Journal:  Cell Mol Life Sci       Date:  2021-03-13       Impact factor: 9.261

9.  Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages.

Authors:  Els Wauters; Pierre Van Mol; Abhishek Dinkarnath Garg; Sander Jansen; Johan Neyts; Joost Wauters; Yannick Van Herck; Lore Vanderbeke; Ayse Bassez; Bram Boeckx; Bert Malengier-Devlies; Anna Timmerman; Thomas Van Brussel; Tina Van Buyten; Rogier Schepers; Elisabeth Heylen; Dieter Dauwe; Christophe Dooms; Jan Gunst; Greet Hermans; Philippe Meersseman; Dries Testelmans; Jonas Yserbyt; Sabine Tejpar; Walter De Wever; Patrick Matthys; Junbin Qian; Diether Lambrechts
Journal:  Cell Res       Date:  2021-01-21       Impact factor: 46.297

10.  Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza.

Authors:  Seppe Cambier; Mieke Metzemaekers; Ana Carolina de Carvalho; Amber Nooyens; Cato Jacobs; Lore Vanderbeke; Bert Malengier-Devlies; Mieke Gouwy; Elisabeth Heylen; Philippe Meersseman; Greet Hermans; Els Wauters; Alexander Wilmer; Dominique Schols; Patrick Matthys; Ghislain Opdenakker; Rafael Elias Marques; Joost Wauters; Jennifer Vandooren; Paul Proost
Journal:  JCI Insight       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.